Rafael Pharmaceuticals

February 13, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ to Investigate Devimistat Combo Therapy for T-cell Lymphoma

News

Rafael Pharmaceuticals‘ devimistat (CPI-613) — which targets the metabolic alterations in cancer cells — will be studied as part of a combination therapy for the treatment of T-cell lymphoma, the company announced. ... Read more

January 14, 2019

Burkitt’s Lymphoma/Leukemia Patients Being Recruited for CPI-613 Phase 2 Trial

News

Rafael Pharmaceuticals is currently enrolling patients with relapsed or refractory Burkitt’s lymphoma/leukemia in a Phase 2 trial to assess the potential of its lead candidate CPI-613. The study (NCT03793140) is ... Read more

September 4, 2018

Penn’s Abramson Cancer Center Added as Second Clinical Trial Site for CPI-613 in T-cell Lymphoma

News

The Abramson Cancer Center at the University of Pennsylvania will serve as a second trial site in the Phase 1 study of CPI-613 for T-cell lymphoma patients, according to Rafael Pharmaceuticals, the drug’s developer. The ... Read more

July 3, 2018

FDA Names CPI-613, Potential Treatment for Burkitt’s Lymphoma, an Orphan Drug

News

The U.S. Food and Drug Administration has again designated Rafael Pharmaceuticals’ lead candidate CPI-613 an orphan drug, this time to further advance it in clinical trials as a potential treatment for Burkitt’s lymphoma. ... Read more